We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$7B
AUM Growth
+$1.45B
Cap. Flow
+$669M
Cap. Flow %
9.56%
Top 10 Hldgs %
35.33%
Holding
139
New
45
Increased
38
Reduced
14
Closed
33

Top Buys

Rank Stock Value
1
NFLX icon
Netflix
NFLX
+$143M
2
UNH icon
UnitedHealth
UNH
+$135M
3
DT icon
Dynatrace
DT
+$86.6M
4
OPEN icon
Opendoor
OPEN
+$75.7M
5
EXAS
Exact Sciences
EXAS
+$73.9M

Top Sells

Rank Stock Value
1
PYPL icon
PayPal
PYPL
+$106M
2
APH icon
Amphenol
APH
+$99.8M
3
GAP
The Gap Inc
GAP
+$96.2M
4
AMZN icon
Amazon
AMZN
+$95.6M
5
CPRT icon
Copart
CPRT
+$71M

Sector Composition

Rank Sector Weight
1 Technology 22.5%
2 Healthcare 21.05%
3 Consumer Discretionary 16.78%
4 Industrials 15.25%
5 Communication Services 11.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPOD
51
DELISTED
Social Capital Hedosophia Holdings Corp. IV
IPOD
$24.6M 0.35%
+1,800,000
New +$22.4M
STRO icon
52
Sutro Biopharma
STRO
$421M
$22.5M 0.32%
103,541
-13,476
-12% -$2.23M
BLUE
53
DELISTED
bluebird bio
BLUE
$18.5M 0.26%
+32,972
New +$20.9M
MILE
54
DELISTED
Metromile, Inc. Common Stock
MILE
$17.9M 0.26%
+1,149,520
New +$15.4M
MRNS
55
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$17.4M 0.25%
1,430,172
+650,447
+83% +$9.07M
ALLO icon
56
Allogene Therapeutics
ALLO
$694M
$12.2M 0.17%
+483,200
New +$15.7M
IMVT icon
57
Immunovant
IMVT
$8.25B
$12M 0.17%
259,200
-276,084
-52% -$12.8M
FBRX icon
58
Forte Biosciences
FBRX
$1.57B
$11.8M 0.17%
+13,000
New +$12.2M
INSM icon
59
Insmed
INSM
$28.6B
$11.2M 0.16%
337,145
– –
SLNO
60
DELISTED
Soleno Therapeutics
SLNO
$11.1M 0.16%
383,880
+168,763
+78% +$4.87M
FSDC
61
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$9.89M 0.14%
899,457
+549,457
+157% +$5.67M
MREO
62
Mereo BioPharma
MREO
$47.3M
$9.84M 0.14%
+2,748,999
New +$6.89M
KURA icon
63
Kura Oncology
KURA
$850M
$8.87M 0.13%
271,500
+152,500
+128% +$5.36M
ORIC icon
64
Oric Pharmaceuticals
ORIC
$1.4B
$8.56M 0.12%
+252,910
New +$7.26M
KDNY
65
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.35M 0.12%
526,455
+298,199
+131% +$4.5M
AGIO icon
66
Agios Pharmaceuticals
AGIO
$1.93B
$8.25M 0.12%
+190,300
New +$7.52M
MRACU
67
DELISTED
Marquee Raine Acquisition Corp. Unit
MRACU
$8.12M 0.12%
+750,000
New +$8.01M
PRLD icon
68
Prelude Therapeutics
PRLD
$390M
$7.95M 0.11%
111,065
-113,935
-51% -$5.67M
KZR
69
DELISTED
Kezar Life Sciences
KZR
$7.36M 0.11%
140,996
+85,406
+154% +$4.75M
ASTR
70
DELISTED
Astra Space, Inc. Class A Common Stock
ASTR
$6.05M 0.09%
+39,867
New +$5.95M
SYRE icon
71
Spyre Therapeutics
SYRE
$9.25B
$5.97M 0.09%
30,350
+9,186
+43% +$1.9M
KALV
72
DELISTED
KalVista Pharmaceuticals
KALV
$5.87M 0.08%
308,900
– –
MIST icon
73
Milestone Pharmaceuticals
MIST
$152M
$5.7M 0.08%
+851,291
New +$5.7M
HAACU
74
DELISTED
Health Assurance Acquisition Corp. SAIL Securities
HAACU
$5.51M 0.08%
+500,000
New +$5.42M
FHTX icon
75
Foghorn Therapeutics
FHTX
$360M
$5.24M 0.07%
+258,700
New +$4.96M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Suvretta Capital Management held 139 positions worth $7B, up 26% from $5.55B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Suvretta Capital Management deployed $669M of net new capital in Q4 2020, opening 45 new positions and adding to 38 existing holdings. Its largest new stake was Dynatrace: 2,179,910 shares worth $94.3M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Amazon, an estimated $95.6M trimmed.

  • Suvretta Capital Management's largest Q4 2020 buy was Dynatrace: 2,179,910 shares worth $94.3M.
  • Suvretta Capital Management added most to Netflix in Q4 2020, an estimated $143M increase.
  • Suvretta Capital Management's biggest Q4 2020 reduction was Amazon, cutting an estimated $95.6M.
  • Suvretta Capital Management fully exited PayPal in Q4 2020, selling an estimated $106M.
  • Suvretta Capital Management's ten largest holdings make up 35% of its $7B portfolio in Q4 2020.
  • Suvretta Capital Management opened 45 new positions and closed 33 in Q4 2020.
  • Suvretta Capital Management's portfolio value rose 26% quarter-over-quarter to $7B.

Based on Suvretta Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.